|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SH3BGRL |
Gene summary for SH3BGRL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SH3BGRL | Gene ID | 6451 |
| Gene name | SH3 domain binding glutamate rich protein like | |
| Gene Alias | HEL-S-115 | |
| Cytomap | Xq21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | O75368 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6451 | SH3BGRL | C38 | Human | Oral cavity | OSCC | 2.76e-07 | 1.14e+00 | 0.172 |
| 6451 | SH3BGRL | C43 | Human | Oral cavity | OSCC | 2.39e-08 | 3.70e-01 | 0.1704 |
| 6451 | SH3BGRL | C46 | Human | Oral cavity | OSCC | 1.23e-07 | 5.26e-01 | 0.1673 |
| 6451 | SH3BGRL | C51 | Human | Oral cavity | OSCC | 1.47e-02 | 2.39e-01 | 0.2674 |
| 6451 | SH3BGRL | C06 | Human | Oral cavity | OSCC | 2.78e-16 | 1.62e+00 | 0.2699 |
| 6451 | SH3BGRL | C07 | Human | Oral cavity | OSCC | 6.54e-05 | 1.31e+00 | 0.2491 |
| 6451 | SH3BGRL | C08 | Human | Oral cavity | OSCC | 1.42e-31 | 9.04e-01 | 0.1919 |
| 6451 | SH3BGRL | LN46 | Human | Oral cavity | OSCC | 1.78e-03 | 5.42e-01 | 0.1666 |
| 6451 | SH3BGRL | LP17 | Human | Oral cavity | LP | 1.28e-05 | 1.11e+00 | 0.2349 |
| 6451 | SH3BGRL | EOLP-1 | Human | Oral cavity | EOLP | 1.72e-11 | 2.85e-01 | -0.0202 |
| 6451 | SH3BGRL | NEOLP-2 | Human | Oral cavity | NEOLP | 7.92e-06 | 3.43e-01 | -0.0196 |
| 6451 | SH3BGRL | NEOLP-3 | Human | Oral cavity | NEOLP | 7.86e-10 | 3.28e-01 | -0.0191 |
| 6451 | SH3BGRL | SYSMH1 | Human | Oral cavity | OSCC | 3.03e-12 | -5.07e-01 | 0.1127 |
| 6451 | SH3BGRL | SYSMH2 | Human | Oral cavity | OSCC | 8.41e-10 | 6.10e-01 | 0.2326 |
| 6451 | SH3BGRL | SYSMH3 | Human | Oral cavity | OSCC | 4.04e-06 | 4.76e-01 | 0.2442 |
| 6451 | SH3BGRL | SYSMH4 | Human | Oral cavity | OSCC | 1.37e-11 | 6.81e-02 | 0.1226 |
| 6451 | SH3BGRL | SYSMH5 | Human | Oral cavity | OSCC | 5.93e-05 | -1.43e-01 | 0.0647 |
| 6451 | SH3BGRL | P3_S6_AK | Human | Skin | AK | 2.89e-02 | -3.41e-01 | -0.3256 |
| 6451 | SH3BGRL | P4_S8_cSCC | Human | Skin | cSCC | 5.11e-08 | -1.61e-01 | -0.3095 |
| 6451 | SH3BGRL | P5_S10_cSCC | Human | Skin | cSCC | 8.06e-14 | -5.67e-01 | -0.299 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SH3BGRL | SNV | Missense_Mutation | c.38N>T | p.Ser13Phe | p.S13F | O75368 | protein_coding | tolerated(0.24) | possibly_damaging(0.604) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SH3BGRL | SNV | Missense_Mutation | novel | c.91N>C | p.Lys31Gln | p.K31Q | O75368 | protein_coding | deleterious(0.04) | probably_damaging(0.954) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SH3BGRL | SNV | Missense_Mutation | novel | c.11G>A | p.Arg4His | p.R4H | O75368 | protein_coding | deleterious(0.03) | benign(0.279) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SH3BGRL | SNV | Missense_Mutation | c.227G>A | p.Arg76His | p.R76H | O75368 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SH3BGRL | SNV | Missense_Mutation | novel | c.56A>C | p.Lys19Thr | p.K19T | O75368 | protein_coding | deleterious(0) | benign(0.288) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SH3BGRL | SNV | Missense_Mutation | c.132N>T | p.Glu44Asp | p.E44D | O75368 | protein_coding | tolerated(0.37) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SH3BGRL | SNV | Missense_Mutation | rs753066745 | c.226N>T | p.Arg76Cys | p.R76C | O75368 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SH3BGRL | SNV | Missense_Mutation | c.260N>G | p.Glu87Gly | p.E87G | O75368 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SH3BGRL | SNV | Missense_Mutation | novel | c.185G>A | p.Gly62Asp | p.G62D | O75368 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SH3BGRL | SNV | Missense_Mutation | novel | c.203N>C | p.Gln68Pro | p.Q68P | O75368 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |